Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
3.050
+0.100 (3.39%)
At close: Jun 26, 2026, 4:00 PM EDT
2.990
-0.060 (-1.97%)
After-hours: Jun 26, 2026, 7:37 PM EDT
Company Description
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases.
The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.
Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Equillium, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 11, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Bruce Steel |
Contact Details
Address: 2223 Avenida De La Playa, Suite 105 La Jolla, California 92037 United States | |
| Phone | 858 240 1200 |
| Website | equilliumbio.com |
Stock Details
| Ticker Symbol | EQ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001746466 |
| CUSIP Number | 29446K106 |
| ISIN Number | US29446K1060 |
| Employer ID | 82-1554746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer and President |
| Christine Zedelmayer M.B.A., P.M.P. | Senior Vice President and Chief Operating Officer |
| Penny Tom CPA | Senior Vice President of Finance and Principal Accounting Officer |
| Michael Moore | Vice President of Investor Relations and Corporate Communications |
| Snehal Naik Ph.D. | Chief Development Officer |
| Dr. Lisette Acevedo | Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2026 | 144 | Filing |
| Jun 4, 2026 | 144 | Filing |
| May 29, 2026 | 8-K | Current Report |
| May 27, 2026 | 144 | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| May 7, 2026 | SCHEDULE 13G | Filing |
| Apr 16, 2026 | EFFECT | Notice of Effectiveness |